Paradigm Biopharmaceuticals (ASX:PAR) Minority Interest: A$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:PAR Paradigm Biopharmaceuticals Ltd ASX:PAR
21 GF Score
Price A$0.16
! 5 Warning Signs
View Full Analysis

What is Paradigm Biopharmaceuticals Minority Interest?

Paradigm Biopharmaceuticals ASX:PAR 21 Minority Interest is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:PAR with a GF Score™ of 21/100. The stock has 5 warning signs investors should review.

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Paradigm Biopharmaceuticals's minority interest for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Paradigm Biopharmaceuticals Minority Interest Historical Data

* Premium members only.

The historical data trend for Paradigm Biopharmaceuticals's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paradigm Biopharmaceuticals Minority Interest Chart

Paradigm Biopharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Minority Interest
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Paradigm Biopharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Minority Interest Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:PAR
21GF Score
Paradigm Biopharmaceuticals Ltd ASX:PAR
Minority Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Paradigm Biopharmaceuticals Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Frequently Asked Questions Learn more about Minority Interest →
What does a Minority Interest of A$0.00 Mil mean?
Paradigm Biopharmaceuticals (ASX:PAR) has a Minority Interest of A$0.00 Mil as of Dec. 2025. Minority interest represents the carrying value of equity from non-controlling shareholders and company partners. View historical data on Paradigm Biopharmaceuticals.
Is Paradigm Biopharmaceuticals' Minority Interest too high?
Paradigm Biopharmaceuticals' current Minority Interest is A$0.00 Mil. Overall, Paradigm Biopharmaceuticals has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Paradigm Biopharmaceuticals' Minority Interest compare to VRTX and REGN?
Paradigm Biopharmaceuticals' Minority Interest of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Minority Interest for a Biotechnology company?
A good Minority Interest depends on the Biotechnology industry context. However, Minority Interest should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Minority Interest mean?
A high Minority Interest can signal that a stock is expensive relative to its fundamentals. Minority interest represents the carrying value of equity from non-controlling shareholders and company partners. View historical data on Paradigm Biopharmaceuticals. Paradigm Biopharmaceuticals's current Minority Interest is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paradigm Biopharmaceuticals stock overvalued right now?
Paradigm Biopharmaceuticals (ASX:PAR) has a current Minority Interest of A$0.00 Mil. The current Minority Interest is A$0.00 Mil. Paradigm Biopharmaceuticals' overall GF Score™ is 21/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Minority Interest calculated?
Minority Interest is calculated from a company's financial statements. For Paradigm Biopharmaceuticals (ASX:PAR), the current Minority Interest is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Paradigm Biopharmaceuticals Business Description

Other Exchanges PBIGF:USAP86:Germany
Address 500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
21GF Score

Get the complete analysis for ASX:PAR

Minority Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.16
Price